A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

NCT02966782 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes (MDS)

Interventions

DRUG: venetoclax
DRUG: azacitidine

Sponsor

AbbVie

Collaborators

[object Object]